Skip to main content
University of Wisconsin-Madison

Events

Events in October 2024

Sunday Monday Tuesday Wednesday Thursday Friday Saturday
September 29, 2024
September 30, 2024
October 1, 2024
October 2, 2024
October 3, 2024
October 4, 2024(1 event)


October 4, 2024

Pharmaceutical Sciences Seminar Series

 

(Drug DISCOVERY Specific Seminar)

  • Dan Flaherty, PhD
  • Purdue University

 

Hosted by Jennifer Golden

777 Highland Ave
Madison, WI 53705
United States

October 5, 2024(1 event)
October 6, 2024
October 7, 2024
October 8, 2024
October 9, 2024(1 event)
October 10, 2024
October 11, 2024(1 event)
October 12, 2024
October 13, 2024
October 14, 2024
October 15, 2024(1 event)
October 16, 2024(1 event)
October 17, 2024
October 18, 2024
October 19, 2024
October 20, 2024
October 21, 2024(1 event)


October 21, 2024

Connect with UW Pharmacy alumni
Join alumni and friends of the University of Wisconsin–Madison School of Pharmacy at the upcoming AAPS PharmSci 360 conference in Salt Lake City.
Several School of Pharmacy faculty and staff, including Clinical Professor and Division of Pharmacy Professional Development Chair Eric Buxton, and Lindy Stoll, Academic Director of Professional Graduate Programs, will be available to talk about School of Pharmacy programs, including the exciting new master’s in Psychoactive Pharmaceutical Investigation and Applied Drug Development, as well as new research from PharmSci faculty and students.
Walk-ins are welcome. The free event includes hors d’oeuvres and drinks.
Woodward on Floor 3 at the Hyatt Regency Salt Lake City 170 South West Temple St., Salt Lake City, UT 84101)

October 22, 2024
October 23, 2024
October 24, 2024
October 25, 2024
October 26, 2024
October 27, 2024
October 28, 2024
October 29, 2024(1 event)
October 30, 2024
October 31, 2024
November 1, 2024(1 event)


November 1, 2024

Pharmaceutical Sciences Seminar Series

 

(Drug DISCOVERY Specific Seminar)

  • Kathie Seley-Radtke, PhD
  • University of Maryland

Development of Pan-Viral Nucleoside Inhibitors

The severity and rapid spread of the coronavirus pandemic served to drive home that we were completely unprepared to fight such an outbreak. As a result, it became clear that there was a critical need for small molecule, orally bioavailable, broad-spectrum drugs that could be stockpiled and readily distributed when the next outbreak occurs. In that regard, for many years nucleos(t)ides have maintained a prominent role as one of the cornerstones of antiviral and anticancer therapeutics, and numerous scaffolds in nucleos(t)ide and nucleic acid drug design have been pursued. One such approach involves adding flexibility to the sugar moieties of nucleos(t)ides, for example, in the highly successful anti-HIV/HBV drug Tenofovir developed by Antonín Holý. In contrast, introduction of flexibility to the nucleobase scaffold has only more recently gained significance with the invention of our fleximers. This modification has led to a significant improvements in antiviral activity, and in some cases endowing the nucleoside with potent broad-spectrum activity across several viral families, when the parent rigid nucleoside was inactive. Another advantage observed is the ability to avoid resistance mechanisms related to point mutations by engaging secondary amino acid residues not previously involved in the mechanism of action. A second series of nucleosides being pursued in our group, involves insertion of a heterocyclic spacer ring in between the two moieties of the bicyclic purine ring system, forming an expanded tricyclic nucleoside with increased aromaticity. This modification has also led to potent antiviral activity, again targeting several different pathogens of pandemic concern. A brief history of their design, synthesis, and recent antiviral findings for these innovative nucleos(t)ide scaffolds will be discussed.

Hosted by Jennifer Golden

777 Highland Ave
Madison, WI 53705
United States

November 2, 2024